Search

Your search keyword '"Instituto Nacional de Enfermedades Respiratorias 'Dr. Emilio Coni'"' showing total 9 results
Start Over Author "Instituto Nacional de Enfermedades Respiratorias 'Dr. Emilio Coni'" Topic influenza, human
9 results on '"Instituto Nacional de Enfermedades Respiratorias 'Dr. Emilio Coni'"'

1. [Parotitis and influenza: unusual association during 2017, in Santa Fe, Argentina].

Author

Kusznierz G, Rudi JM, Garate VV, Uboldi A, Cociglio R, Beltramino JC, Pierini J, Sioli N, Pigliacampo G, Cesoni A, D Jorge J, Cantero C, Schoult P, Cecilia F, Baumesteir E, Pastor C, Vidal G, and Cudós C

Subjects
Adolescent, Adult, Argentina epidemiology, Child, Child, Preschool, Diagnosis, Differential, Female, Humans, Infant, Male, Seasons, Young Adult, Influenza, Human virology, Parotitis epidemiology, Parotitis virology
Abstract

Background: Parotitis is an acute viral disease characterized by swelling and pain in one or both salivary glands, submaxillary or submental, fever, headache, muscle ache and/or fatigue., Aim: To investigate the occurrence of influenza virus infection in parotitis cases in a population of Santa Fe during 2017 and analyze clinical and epidemiological characteristics of the cases., Methods: We studied patients with diagnosis of mumps without age restriction, who came for examination from week 26 to the network of clinicians forming the Sentinel Influenza Unit in Santa Fe., Results: Between epidemiological weeks 26 and 44, 22 clinical parotitis cases we enrolled. The influenza virus was detected in 68.2%, influenza A (H3N2) 93%, and influenza B, 7%. The clinical signs of cases were mild, with an average swelling development of 5 days and no complications. 74% presented with influenza-like illness in tandem with parotitis., Conclusions: This study provides evidence that a proportion of children presenting with parotitis had influenza A(H3N2) virus infection. It is necessary to implement systematic surveillance of parotitis associated with influenza and differential diagnosis even in the absence of respiratory symptoms.

Published
2019
Full Text
View/download PDF

2. Distribution of influenza virus types by age using case-based global surveillance data from twenty-nine countries, 1999-2014.

Author

Caini S, Spreeuwenberg P, Kusznierz GF, Rudi JM, Owen R, Pennington K, Wangchuk S, Gyeltshen S, Ferreira de Almeida WA, Pessanha Henriques CM, Njouom R, Vernet MA, Fasce RA, Andrade W, Yu H, Feng L, Yang J, Peng Z, Lara J, Bruno A, de Mora D, de Lozano C, Zambon M, Pebody R, Castillo L, Clara AW, Matute ML, Kosasih H, Nurhayati, Puzelli S, Rizzo C, Kadjo HA, Daouda C, Kiyanbekova L, Ospanova A, Mott JA, Emukule GO, Heraud JM, Razanajatovo NH, Barakat A, El Falaki F, Huang SQ, Lopez L, Balmaseda A, Moreno B, Rodrigues AP, Guiomar R, Ang LW, Lee VJM, Venter M, Cohen C, Badur S, Ciblak MA, Mironenko A, Holubka O, Bresee J, Brammer L, Hoang PVM, Le MTQ, Fleming D, Séblain CE, Schellevis F, and Paget J

Subjects
Adolescent, Adult, Age Factors, Aged, Child, Child, Preschool, Databases, Factual, Female, Global Health, Humans, Infant, Infant, Newborn, Influenza, Human diagnosis, Male, Middle Aged, Young Adult, Influenza A Virus, H1N1 Subtype isolation & purification, Influenza A Virus, H3N2 Subtype isolation & purification, Influenza, Human virology
Abstract

Background: Influenza disease burden varies by age and this has important public health implications. We compared the proportional distribution of different influenza virus types within age strata using surveillance data from twenty-nine countries during 1999-2014 (N=358,796 influenza cases)., Methods: For each virus, we calculated a Relative Illness Ratio (defined as the ratio of the percentage of cases in an age group to the percentage of the country population in the same age group) for young children (0-4 years), older children (5-17 years), young adults (18-39 years), older adults (40-64 years), and the elderly (65+ years). We used random-effects meta-analysis models to obtain summary relative illness ratios (sRIRs), and conducted meta-regression and sub-group analyses to explore causes of between-estimates heterogeneity., Results: The influenza virus with highest sRIR was A(H1N1) for young children, B for older children, A(H1N1)pdm2009 for adults, and (A(H3N2) for the elderly. As expected, considering the diverse nature of the national surveillance datasets included in our analysis, between-estimates heterogeneity was high (I 2 >90%) for most sRIRs. The variations of countries' geographic, demographic and economic characteristics and the proportion of outpatients among reported influenza cases explained only part of the heterogeneity, suggesting that multiple factors were at play., Conclusions: These results highlight the importance of presenting burden of disease estimates by age group and virus (sub)type.

Published
2018
Full Text
View/download PDF

3. Characteristics of seasonal influenza A and B in Latin America: Influenza surveillance data from ten countries.

Author

Caini S, Alonso WJ, Balmaseda A, Bruno A, Bustos P, Castillo L, de Lozano C, de Mora D, Fasce RA, Ferreira de Almeida WA, Kusznierz GF, Lara J, Matute ML, Moreno B, Pessanha Henriques CM, Rudi JM, El-Guerche Séblain C, Schellevis F, and Paget J

Subjects
Humans, Influenza, Human virology, Latin America, Population Surveillance, Seasons, Tropical Climate, Influenza A virus, Influenza B virus, Influenza, Human epidemiology
Abstract

Introduction: The increased availability of influenza surveillance data in recent years justifies an actual and more complete overview of influenza epidemiology in Latin America. We compared the influenza surveillance systems and assessed the epidemiology of influenza A and B, including the spatio-temporal patterns of influenza epidemics, in ten countries and sub-national regions in Latin America., Methods: We aggregated the data by year and country and characteristics of eighty-two years were analysed. We calculated the median proportion of laboratory-confirmed influenza cases caused by each virus strain, and compared the timing and amplitude of the primary and secondary peaks between countries., Results: 37,087 influenza cases were reported during 2004-2012. Influenza A and B accounted for a median of 79% and, respectively, 21% of cases in a year. The percentage of influenza A cases that were subtyped was 82.5%; for influenza B, 15.6% of cases were characterized. Influenza A and B were dominant in seventy-five (91%) and seven (9%) years, respectively. In half (51%) of the influenza A years, influenza A(H3N2) was dominant, followed by influenza A(H1N1)pdm2009 (41%) and pre-pandemic A(H1N1) (8%). The primary peak of influenza activity was in June-September in temperate climate countries, with little or no secondary peak. Tropical climate countries had smaller primary peaks taking place in different months and frequently detectable secondary peaks., Conclusions: We found that good influenza surveillance data exists in Latin America, although improvements can still be made (e.g. a better characterization of influenza B specimens); that influenza B plays a considerable role in the seasonal influenza burden; and that there is substantial heterogeneity of spatio-temporal patterns of influenza epidemics. To improve the effectiveness of influenza control measures in Latin America, tropical climate countries may need to develop innovative prevention strategies specifically tailored to the spatio-temporal patterns of influenza in this region.

Published
2017
Full Text
View/download PDF

4. Temporal Patterns of Influenza A and B in Tropical and Temperate Countries: What Are the Lessons for Influenza Vaccination?

Author

Caini S, Andrade W, Badur S, Balmaseda A, Barakat A, Bella A, Bimohuen A, Brammer L, Bresee J, Bruno A, Castillo L, Ciblak MA, Clara AW, Cohen C, Cutter J, Daouda C, de Lozano C, De Mora D, Dorji K, Emukule GO, Fasce RA, Feng L, Ferreira de Almeida WA, Guiomar R, Heraud JM, Holubka O, Huang QS, Kadjo HA, Kiyanbekova L, Kosasih H, Kusznierz G, Lara J, Li M, Lopez L, Mai Hoang PV, Pessanha Henriques CM, Matute ML, Mironenko A, Moreno B, Mott JA, Njouom R, Nurhayati, Ospanova A, Owen R, Pebody R, Pennington K, Puzelli S, Quynh Le MT, Razanajatovo NH, Rodrigues A, Rudi JM, Tzer Pin Lin R, Venter M, Vernet MA, Wangchuk S, Yang J, Yu H, Zambon M, Schellevis F, and Paget J

Subjects
Humans, Influenza, Human epidemiology, Retrospective Studies, Seasons, Tropical Climate, Influenza A virus immunology, Influenza B virus immunology, Influenza, Human prevention & control, Vaccination
Abstract

Introduction: Determining the optimal time to vaccinate is important for influenza vaccination programmes. Here, we assessed the temporal characteristics of influenza epidemics in the Northern and Southern hemispheres and in the tropics, and discuss their implications for vaccination programmes., Methods: This was a retrospective analysis of surveillance data between 2000 and 2014 from the Global Influenza B Study database. The seasonal peak of influenza was defined as the week with the most reported cases (overall, A, and B) in the season. The duration of seasonal activity was assessed using the maximum proportion of influenza cases during three consecutive months and the minimum number of months with ≥80% of cases in the season. We also assessed whether co-circulation of A and B virus types affected the duration of influenza epidemics., Results: 212 influenza seasons and 571,907 cases were included from 30 countries. In tropical countries, the seasonal influenza activity lasted longer and the peaks of influenza A and B coincided less frequently than in temperate countries. Temporal characteristics of influenza epidemics were heterogeneous in the tropics, with distinct seasonal epidemics observed only in some countries. Seasons with co-circulation of influenza A and B were longer than influenza A seasons, especially in the tropics., Discussion: Our findings show that influenza seasonality is less well defined in the tropics than in temperate regions. This has important implications for vaccination programmes in these countries. High-quality influenza surveillance systems are needed in the tropics to enable decisions about when to vaccinate.

Published
2016
Full Text
View/download PDF

5. Epidemiological and virological characteristics of influenza B: results of the Global Influenza B Study.

Author

Caini S, Huang QS, Ciblak MA, Kusznierz G, Owen R, Wangchuk S, Henriques CM, Njouom R, Fasce RA, Yu H, Feng L, Zambon M, Clara AW, Kosasih H, Puzelli S, Kadjo HA, Emukule G, Heraud JM, Ang LW, Venter M, Mironenko A, Brammer L, Mai le TQ, Schellevis F, Plotkin S, and Paget J

Subjects
Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Child, Child, Preschool, Disease Outbreaks statistics & numerical data, Female, Humans, Infant, Infant, Newborn, Influenza A virus, Influenza Vaccines, Male, Middle Aged, Seasons, Young Adult, Global Health, Influenza B virus genetics, Influenza, Human epidemiology, Influenza, Human virology, Population Surveillance
Abstract

Introduction: Literature on influenza focuses on influenza A, despite influenza B having a large public health impact. The Global Influenza B Study aims to collect information on global epidemiology and burden of disease of influenza B since 2000., Methods: Twenty-six countries in the Southern (n = 5) and Northern (n = 7) hemispheres and intertropical belt (n = 14) provided virological and epidemiological data. We calculated the proportion of influenza cases due to type B and Victoria and Yamagata lineages in each country and season; tested the correlation between proportion of influenza B and maximum weekly influenza-like illness (ILI) rate during the same season; determined the frequency of vaccine mismatches; and described the age distribution of cases by virus type., Results: The database included 935 673 influenza cases (2000-2013). Overall median proportion of influenza B was 22·6%, with no statistically significant differences across seasons. During seasons where influenza B was dominant or co-circulated (>20% of total detections), Victoria and Yamagata lineages predominated during 64% and 36% of seasons, respectively, and a vaccine mismatch was observed in ≈25% of seasons. Proportion of influenza B was inversely correlated with maximum ILI rate in the same season in the Northern and (with borderline significance) Southern hemispheres. Patients infected with influenza B were usually younger (5-17 years) than patients infected with influenza A., Conclusion: Influenza B is a common disease with some epidemiological differences from influenza A. This should be considered when optimizing control/prevention strategies in different regions and reducing the global burden of disease due to influenza., (© 2015 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.)

Published
2015
Full Text
View/download PDF

6. Distribution of influenza virus types by age using case-based global surveillance data from twenty-nine countries, 1999-2014

Author

François G. Schellevis, Raquel Guiomar, Zhibin Peng, Phuong Vu Mai Hoang, Brechla Moreno, Juan Yang, Cheryl Cohen, Lynnette Brammer, Jenny Lara, Hongjie Yu, Mai thi Quynh Le, Joshua A. Mott, Rodrigo Fasce, Gabriela Kusznierz, Simona Puzelli, Doménica de Mora, Leticia Castillo, Selim Badur, Akerke Ospanova, Vernon J. Lee, Liza Lopez, Richard Njouom, Douglas M. Fleming, Coulibaly Daouda, Nurhayati, Juan Manuel Rudi, Clotilde El-Guerche Séblain, Li Wei Ang, Joseph S. Bresee, Celina de Lozano, Sonam Gyeltshen, Maria Zambon, Maria Luisa Matute, Norosoa Harline Razanajatovo, Saverio Caini, Amal Barakat, Marie-Astrid Vernet, Alla Mironenko, Angel Balmaseda, Alexey Clara, Walquiria Aparecida Ferreira de Almeida, Richard Pebody, Herman Kosasih, Cláudio Maierovitch Pessanha Henriques, Marietjie Venter, Caterina Rizzo, Meral Akcay Ciblak, Olha Holubka, Gideon O. Emukule, Fatima el Falaki, Winston Andrade, Herve A. Kadjo, Alfredo Bruno, Kate Pennington, Lyazzat Kiyanbekova, Ana Paula Rodrigues, Rhonda Owen, John Paget, Peter Spreeuwenberg, Sue Q. Huang, Jean-Michel Heraud, Sonam Wangchuk, Luzhao Feng, Netherlands Institute for Health Services Research, Instituto Nacional de Enfermedades Respiratorias 'Dr. Emilio Coni', Department of Health and Ageing, Influenza Surveillance Section, Surveillance Branch, Office of Health Protection (DHAISS), Department of Health and Ageing, Influenza Surveillance Section, Surveillance Branch, Office of Health Protection, Woden, ACT, Australia, Office of Health Protection, Woden, ACT, Australia (DHAISS), Ministry of Health [Bhoutan], Ministry of Health [Brasília, Brazil], Centre Pasteur du Cameroun, Réseau International des Instituts Pasteur (RIIP), Instituto de Salud Pública de Chile (ISP), Chinese Centre for Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Ministry of Health [Costa Rica], Instituto Nacional de Investigación en Salud Pública [Guayaquil, Ecuador] (INSPI), Ministerio de Salud de El Salvador (MINSAL), Public Health England [London], Ministerio de Salud Publica y Asistencia Social [Guatemala] (MSPAS), US Centers for Disease Control, Ministry of Health [Honduras] (SESAL), US Naval Medical Research Unit n°2, Istituto Superiore di Sanita [Rome], Institut Pasteur de Côte d'Ivoire, Institut National d'Hygiène Publique [Côte d'Ivoire] (INHP), Astana Center of Sanitary Epidemiology Expertise, Centers for Disease Control and Prevention [Kenya], U.S. Public Health Service (USPHS), Unité de Virologie [Antananarivo, Madagascar] (IPM), Institut Pasteur de Madagascar, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Ministry of Health [Morocco], Institute of Environmental Science and Research (ESR), Ministry of Health [Nicaragua] (MINSA), National Influenza Center, Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Ministry of Health [Singapore], Centers for Disease Control and Prevention, University of Pretoria [South Africa], University of the Witwatersrand [Johannesburg] (WITS), National Institute for Communicable Diseases [Johannesburg] (NICD), Istanbul University, National Academy of Medical Sciences of Ukraine, Centers for Disease Control and Prevention [Atlanta] (CDC), National Institute of Hygiene and Epidemiology [Hanoi, Vietnam] (NIHE), Chercheur indépendant, Sanofi Pasteur [Lyon, France], VU University Medical Center [Amsterdam], The Global Influenza B Study is funded by an unrestricted research grant from Sanofi Pasteur., The Global Influenza B Study group also includes the following members: Binay Thapa 4, Sangay Zangmo 4, Guy Vernet 6, Patricia Bustos 7, Patricio Loyola 7, Joanna Ellis 12, Antonino Bella 19, Maria Rita Castrucci 18, Gulzhan Muratbayeva 45, Julia Guillebaud 26, Laurence Randrianasolo 46, Ausenda Machado 47, Pedro Pechirra 32, Jeffery Cutter 34, Raymond Tzer Pin Lin 34. 45 Centers for Disease Control and Prevention, Central Asia Regional Office, Almaty, Kazakhstan 46 Epidemiology Unit, Institut Pasteur of Madagascar, Antananarivo, Madagascar 47 National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal, APH - Quality of Care, APH - Aging & Later Life, and General practice

Subjects
0301 basic medicine, Male, Databases, Factual, Distribution (economics), CHILDREN, Global Health, 0302 clinical medicine, Influenza A Virus, H1N1 Subtype, 1108 Medical Microbiology, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Influenza A Virus, H3N2 subtype, 030212 general & internal medicine, Young adult, Child, POPULATION, education.field_of_study, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Age Factors, Middle Aged, 3. Good health, Global Influenza B Study group, Infectious Diseases, INFECTIONS, Influenza A virus, Child, Preschool, H3N2 Subtype, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Female, BURDEN, Life Sciences & Biomedicine, Age distribution, 0605 Microbiology, Adult, medicine.medical_specialty, Surveillance data, Adolescent, Population, UNITED-STATES, Microbiology, Virus, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, Young Adult, Age Distribution, Influenza, Human, medicine, Humans, H1N1 Subtype, COHORT, lcsh:RC109-216, education, Disease burden, METAANALYSIS, Aged, Science & Technology, business.industry, Public health, Influenza A Virus, H3N2 Subtype, Infant, Newborn, Infant, 1103 Clinical Sciences, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, Estados de Saúde e de Doença, Influenza B Virus, Influenza, Influenza B virus, Meta-analysis, 030104 developmental biology, H1N1 subtype, Virus type, RISK-FACTORS, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Demography
Abstract

The database of the Global Influenza B Study was created by collecting surveillance datasets from each of the participating countries. These national datasets are owned by the participating countries, and thus cannot be shared publicly. Researchers interested in obtaining the country-specific datasets may contact the individuals listed below for further details regarding data access.Argentina (Santa Fe Province): Gabriela Kusznierz (labconi@yahoo.com.ar)Australia: Kate Pennington (kate.pennington@health.gov.au)Bhutan: Sonam Wangchuk (swangchuk@health.gov.bt)Brazil: Cláudio Maierovitch Pessanha Henriques (claudio.henriques@saude.gov.br)Cameroon: Guy Vernet (vernet@pasteur-yaounde.org)Chile: Rodrigo Fasce (rfasce@ispch.cl)China: Feng Luzhao (fenglz@chinacdc.cn)Costa Rica: Alexey W. Clara (wclara@cdc.gov)Ecuador: Alfredo Bruno (alfredobruno@yahoo.es)El Salvador: Alexey W. Clara (wclara@cdc.gov)England: Maria Zambon (maria.zambon@phe.gov.uk)Guatemala: Alexey W. Clara (wclara@cdc.gov)Honduras: Alexey W. Clara (wclara@cdc.gov)Indonesia: Herman Kosasih (hermaninarespond@gmail.com)Italy: Caterina Rizzo (caterina.rizzo@iss.it)Ivory Coast: Herve A. Kadjo (hervekadjo@pasteur.ci)Kazakhstan: Gulzhan Muratbayeva (hnv2@cdc.gov)Kenya: Joshua Mott (zud9@cdc.gov)Madagascar: Jean-Michel Heraud (jmheraud@pasteur.mg)Morocco: Amal Barakat (amal.barakat@yahoo.fr)New Zealand: Sue Huang (sue.huang@esr.cri.nz)Nicaragua: Alexey W. Clara (wclara@cdc.gov)Panama: Alexey W. Clara (wclara@cdc.gov)Portugal: Ana Paula Rodrigues (ana.rodrigues@insa.min-saude.pt)Singapore: Vernon Lee (vernonljm@hotmail.com)South Africa: Cheryl Cohen (cherylc@nicd.ac.za)Turkey: Meral Akcay Ciblak (ciblakm@yahoo.com)Ukraine: Alla Mironenko (miralla@ukr.net)Viet Nam: Le Thi Quinh Mai (lom9@hotmail.com); International audience; BACKGROUND:Influenza disease burden varies by age and this has important public health implications. We compared the proportional distribution of different influenza virus types within age strata using surveillance data from twenty-nine countries during 1999-2014 (N=358,796 influenza cases).METHODS:For each virus, we calculated a Relative Illness Ratio (defined as the ratio of the percentage of cases in an age group to the percentage of the country population in the same age group) for young children (0-4 years), older children (5-17 years), young adults (18-39 years), older adults (40-64 years), and the elderly (65+ years). We used random-effects meta-analysis models to obtain summary relative illness ratios (sRIRs), and conducted meta-regression and sub-group analyses to explore causes of between-estimates heterogeneity.RESULTS:The influenza virus with highest sRIR was A(H1N1) for young children, B for older children, A(H1N1)pdm2009 for adults, and (A(H3N2) for the elderly. As expected, considering the diverse nature of the national surveillance datasets included in our analysis, between-estimates heterogeneity was high (I2>90%) for most sRIRs. The variations of countries' geographic, demographic and economic characteristics and the proportion of outpatients among reported influenza cases explained only part of the heterogeneity, suggesting that multiple factors were at play.CONCLUSIONS:These results highlight the importance of presenting burden of disease estimates by age group and virus (sub)type.

Published
2018

7. The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century

Author

John Paget, Olga Bessonova, Joseph S. Bresee, Norosoa Harline Razanajatovo, Saverio Caini, Binay Thapa, Francisco José de Paula Júnior, Jenny Lara Araya, Florette K. Treurnicht, Walquiria Aparecida Ferreira de Almeida, Brechla Moreno Arévalo, Zhibin Peng, Raquel Guiomar, Gabriela Kusznierz, Q. Sue Huang, Herman Kosasih, Antonino Bella, Doménica de Mora, Rakhee Palekar, Olha Holubka, Maria R. Castrucci, Rudevelinda Rivera, Phuong Vu Mai Hoang, Gideon O. Emukule, Rodrigo Fasce, Rocio Higueros, Sandra S. Chaves, Fatima el Falaki, Mai T. Q. Le, Herve A. Kadjo, Patricia Bustos, Luzhao Feng, Ainash Makusheva, Vernon J. Lee, Richard Njouom, Ana Paula Rodrigues, Coulibaly Daouda, Gé Donker, Alfredo Bruno, Alla Mironenko, Cheryl Cohen, Jean-Michel Heraud, Li Wei Ang, Sonam Wangchuk, Mónica Jeannette Barahona de Gámez, Maria Zambon, Clotilde El Guerche-Séblain, Angel Balmaseda, Lynnette Brammer, Amal Barakat, Richard Pebody, Adam Meijer, Verònica Vera Garate, Tim Wood, Netherlands Institute for Health Services Research [Utrecht] (NIVEL), Instituto Nacional de Enfermedades Respiratorias Dr. Emilio Coni [Santa Fe, Argentina] (INER), Ministry of Health [Bhoutan], Ministry of Health [Brasília, Brazil], Centre Pasteur du Cameroun, Réseau International des Instituts Pasteur (RIIP), Instituto de Salud Pública de Chile (ISP), Chinese Center for Disease Control and Prevention, Ministry of Health [Costa Rica], Instituto Nacional de Investigación en Salud Pública [Guayaquil, Ecuador] (INSPI), Ministerio de Salud de El Salvador (MINSAL), Public Health England [London], Ministerio de Salud Publica y Asistencia Social [Guatemala] (MSPAS), Ministry of Health [Honduras] (SESAL), US Naval Medical Research Unit No.2 [Jakarta, Indonesia] (NAMRU-2), Naval Medical Research Center [Silver Spring, USA] (NMRC), Istituto Superiore di Sanita [Rome], Institut Pasteur de Côte d'Ivoire, Institut National de Santé Publique d'Abidjan-INSP, Ministry of Healthcare [Kazakhstan], Centers for Disease Control and Prevention [Atlanta] (CDC), Centers for Disease Control and Prevention, Centers for Disease Control and Prevention [Kenya], Unité de Virologie [Antananarivo, Madagascar] (IPM), Institut Pasteur de Madagascar, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Institut National d'Hygiène [Maroc], National Institute for Public Health and the Environment [Bilthoven] (RIVM), Institute of Environmental Science and Research (ESR), Ministry of Health [Nicaragua] (MINSA), Pan American Health Organization [Washington] (PAHO), Instituto Conmemorativo Gorgas de Estudios de la Salud [Panamá], Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Ministry of Health [Singapore], National Institute for Communicable Diseases [Johannesburg] (NICD), University of the Witwatersrand [Johannesburg] (WITS), National Academy of Sciences of Ukraine (NASU), National Institute of Hygiene and Epidemiology [Hanoi, Vietnam] (NIHE), Sanofi Pasteur [Lyon, France], The study is supported by a research grant from Sanofi Pasteur: the ‘Global Epidemiology of Influenza B’ research project. The funder provided support in the form of salaries for two authors (CEGS and JP) but did not have any additional role in the data collection, analysis, decision to publish, or preparation of the manuscript., The 'Global Influenza B Study team' (group authorship) includes the following scientists: Juan Manuel Rudi (jmrudi@anlis.gov.ar), National Institute of Respiratory Diseases 'Emilio Coni', Santa Fe, Argentina, Dorji Wangchuk (dorjiwangchuk@health.gov.bt) and Sangay Zangmo (szangmo@health.gov.bt), Royal Centre for Disease Control, Department of Public Health, Ministry of Health, Thimphu, Bhutan, Daiana Araujo da Silva (daiana.silva@saude.gov.br), Ministry of Health, Department of Surveillance of Transmissible Diseases, Brasília/DF, Brazil, Winston Andrade (wandrade@ispch.cl), Sub-Department of Viral Diseases, Instituto de Salud Pública de Chile, Santiago, Chile, Jiandong Zheng (zhengjd@chinacdc.cn) and Ying Qin (qinying@chinacdc.cn), Division of Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, P.R. China, Joanna Ellis (joanna.ellis@phe.gov.uk), Public Health England, London, United Kingdom, Simona Puzelli (simona.puzelli@iss.it), National Influenza Center, Department of Infectious Diseases, National Institute of Health, Rome, Italy, Caterina Rizzo (rizzocaterina@gmail.com), Bambino Gesù Children's Hospital, Rome, Italy, Linus Ndegwa (ikf7@cdc.gov), Influenza Program, Centers for Disease Control and Prevention, Nairobi, Kenya, Marit MA de Lange (marit.de.lange@rivm.nl) and Anne C. Teirlinck (anne.teirlinck@rivm.nl), National Institute for Public Health and the Environment, Centre for Infectious Diseases, Epidemiology and Surveillance, Bilthoven, The Netherlands, Jeffery Cutter (jeffery_cutter@moh.gov.sg) and Raymond Tzer Pin Lin (raymond_lin@moh.gov.sg), Public Health Group, Ministry of Health, Singapore, Singapore, Than T. Le (lmot82@yahoo.com), National Institute of Hygiene and Epidemiology, Hanoi, Vietnam, and Peter Kinuthia 42 (polorien@gmail.com), IHRC Inc., Atlanta, USA.

Subjects
RNA viruses, Male, Infecções Respiratórias, 0301 basic medicine, Viral Diseases, medicine.disease_cause, MESH: Influenza Vaccines, Seasonal influenza, Influenza A Virus, H1N1 Subtype, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Epidemiology, Medicine and Health Sciences, Influenza A virus, 030212 general & internal medicine, MESH: Influenza B virus, Pathology and laboratory medicine, Northern Hemisphere, Vaccines, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Multidisciplinary, Geography, MESH: Influenza, Human, virus diseases, Medical microbiology, 3. Good health, Infectious Diseases, Influenza Vaccines, Population Surveillance, Viruses, Epidemiological Monitoring, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Medicine, Southern Hemisphere, Female, Age distribution, Seasons, Pathogens, MESH: History, 21st Century, Research Article, medicine.medical_specialty, Infectious Disease Control, Science, MESH: Influenza A virus, Biology, Microbiology, History, 21st Century, Virus, MESH: Population Surveillance, MESH: Influenza A Virus, H1N1 Subtype, 03 medical and health sciences, Age Distribution, Population Metrics, Influenza, Human, medicine, Influenza viruses, Humans, Epidemics, MESH: Epidemics, Disease burden, MESH: Humans, Biology and life sciences, Population Biology, Organisms, Viral pathogens, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, Estados de Saúde e de Doença, Virology, Influenza, MESH: Male, Microbial pathogens, Earth sciences, Influenza B virus, Vaccine mismatch, 030104 developmental biology, Virus type, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Epidemiological Monitoring, Geographic areas, MESH: Seasons, MESH: Female, Orthomyxoviruses
Abstract

Free PMC article: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31513690/ We describe the epidemiological characteristics, pattern of circulation, and geographical distribution of influenza B viruses and its lineages using data from the Global Influenza B Study. We included over 1.8 million influenza cases occurred in thirty-one countries during 2000-2018. We calculated the proportion of cases caused by influenza B and its lineages; determined the timing of influenza A and B epidemics; compared the age distribution of B/Victoria and B/Yamagata cases; and evaluated the frequency of lineage-level mismatch for the trivalent vaccine. The median proportion of influenza cases caused by influenza B virus was 23.4%, with a tendency (borderline statistical significance, p = 0.060) to be higher in tropical vs. temperate countries. Influenza B was the dominant virus type in about one every seven seasons. In temperate countries, influenza B epidemics occurred on average three weeks later than influenza A epidemics; no consistent pattern emerged in the tropics. The two B lineages caused a comparable proportion of influenza B cases globally, however the B/Yamagata was more frequent in temperate countries, and the B/Victoria in the tropics (p = 0.048). B/Yamagata patients were significantly older than B/Victoria patients in almost all countries. A lineage-level vaccine mismatch was observed in over 40% of seasons in temperate countries and in 30% of seasons in the tropics. The type B virus caused a substantial proportion of influenza infections globally in the 21st century, and its two virus lineages differed in terms of age and geographical distribution of patients. These findings will help inform health policy decisions aiming to reduce disease burden associated with seasonal influenza. info:eu-repo/semantics/publishedVersion

Published
2019

8. Temporal Patterns of Influenza A and B in Tropical and Temperate Countries: What Are the Lessons for Influenza Vaccination?

Author

Marietjie Venter, Juan Yang, Simona Puzelli, Antonino Bella, Joshua A. Mott, Rodrigo Fasce, Coulibaly Daouda, Jenny Lara, Hongjie Yu, Winston Andrade, Selim Badur, Cláudio Maierovitch Pessanha Henriques, François G. Schellevis, Jean-Michel Heraud, Akerke Ospanova, Sonam Wangchuk, Brechla Moreno, Herve A. Kadjo, Raymond T. P. Lin, Juan Manuel Rudi, Walquiria Aparecida Ferreira de Almeida, Gabriela Kusznierz, Joseph S. Bresee, Cheryl Cohen, Mai thi Quynh Le, Rhonda Owen, Maria Zambon, Maria Luisa Matute, Kunzang Dorji, Kate Pennington, Global Influenza B Study, Herman Kosasih, Nurhayati, Alla Mironenko, Ming Li, Angel Balmaseda, Alexey Clara, Alfredo Bruno, Richard Njouom, Phuong Vu Mai Hoang, Ana Paula Rodrigues, Celina de Lozano, Luzhao Feng, Olha Holubka, Amal Barakat, Lyazzat Kiyanbekova, Norosoa Harline Razanajatovo, Saverio Caini, Meral Akcay Ciblak, Raquel Guiomar, Richard Pebody, Leticia Castillo, Gideon O. Emukule, Liza Lopez, Doménica de Mora, Jeffery Cutter, Q. Sue Huang, Marie-Astrid Vernet, Abderrahman Bimohuen, John Paget, Lynnette Brammer, General practice, EMGO - Quality of care, Netherlands Institute for Health Services Research, Instituto de Salud Pública de Chile (ISP), Istanbul University, Ministry of Health [Nicaragua] (MINSA), Ministry of Health [Morocco], Istituto Superiore di Sanita [Rome], Centers for Disease Control and Prevention [Atlanta] (CDC), Centers for Disease Control and Prevention, Instituto Nacional de Investigación en Salud Pública [Guayaquil, Ecuador] (INSPI), Ministerio de Salud Publica y Asistencia Social [Guatemala] (MSPAS), US Centers for Disease Control, University of the Witwatersrand [Johannesburg] (WITS), Ministry of Health, Institut Pasteur de Côte d'Ivoire, Réseau International des Instituts Pasteur (RIIP), Ministerio de Salud de El Salvador (MINSAL), Ministry of Health [Bhoutan], US Centers for Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Instituto nacional de saude, Unité de Virologie [Antananarivo, Madagascar] (IPM), Institut Pasteur de Madagascar, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), National Academy of Medical Sciences of Ukraine, Institute of Environmental Science and Research (ESR), Astana Center of Sanitary Epidemiology Expertise, US Naval Medical Research Unit n°2, Instituto Nacional de Enfermedades Respiratorias 'Dr. Emilio Coni', Ministry of Health [Costa Rica], National Institute of Hygiene and Epidemiology [Hanoi, Vietnam] (NIHE), Ministry of Health [Honduras] (SESAL), National Influenza Center, Centre Pasteur du Cameroun, Office of Health Protection, Woden, ACT, Australia (DHAISS), Public Health England [London], National Institute of Health, University of Pretoria [South Africa], The Global Influenza B Study is supported by an unrestricted research grant from Sanofi Pasteur. The study sponsor had no role in the design of the study, in the collection, analysis, and interpretation of data, in the writing of the report, and and in the decision to submit the paper for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. The study sponsor had no access to the data in the study.

Subjects
Infecções Respiratórias, Influenza Viruses, Epidemiology, Gripe, Pathology and Laboratory Medicine, Geographical locations, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, DRIVERS, Estados de Saúde, Public and Occupational Health, SUB-SAHARAN AFRICA, lcsh:Science, MESH: Influenza B virus, Northern Hemisphere, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Geography, MESH: Influenza, Human, Vaccination, virus diseases, 3. Good health, Global Influenza B Study, MESH: Tropical Climate, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Science & Technology - Other Topics, Immunology, Disease Surveillance, SEASONAL INFLUENZA, Microbiology, Influenza Vaccin, 03 medical and health sciences, Influenza Vaccination, SURVEILLANCE, Humans, Microbial Pathogens, Retrospective Studies, MESH: Humans, Science & Technology, lcsh:R, Organisms, Correction, Influenza a, MESH: Retrospective Studies, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, medicine.disease, Virology, Influenza, MADAGASCAR, lcsh:Q, Preventive Medicine, People and places, Demography, RNA viruses, Viral Diseases, lcsh:Medicine, medicine.disease_cause, Tropical climate, Medicine and Health Sciences, Influenza A virus, 030212 general & internal medicine, Multidisciplinary, Medical microbiology, Vaccination and Immunization, Multidisciplinary Sciences, Infectious Diseases, Viruses, Human mortality from H5N1, Southern Hemisphere, Seasons, Pathogens, Brazil, Research Article, Infectious Disease Control, General Science & Technology, 030231 tropical medicine, MESH: Influenza A virus, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], MD Multidisciplinary, Influenza, Human, Temperate climate, medicine, Tropical Climate, Biology and life sciences, business.industry, Other Research Radboud Institute for Health Sciences [Radboudumc 0], Viral pathogens, Tropics, MESH: Vaccination, South America, Seasonality, Earth sciences, Influenza B virus, Infectious Disease Surveillance, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Geographic areas, MESH: Seasons, Orthomyxoviruses
Abstract

Erratum in - Correction: Temporal Patterns of Influenza A and B in Tropical and Temperate Countries: What Are the Lessons for Influenza Vaccination? PLoS One. 2016 May 2;11(5):e0155089. doi: 10.1371/journal.pone.0155089. Introduction: Determining the optimal time to vaccinate is important for influenza vaccination programmes. Here, we assessed the temporal characteristics of influenza epidemics in the Northern and Southern hemispheres and in the tropics, and discuss their implications for vaccination programmes. Methods: This was a retrospective analysis of surveillance data between 2000 and 2014 from the Global Influenza B Study database. The seasonal peak of influenza was defined as the week with the most reported cases (overall, A, and B) in the season. The duration of seasonal activity was assessed using the maximum proportion of influenza cases during three consecutive months and the minimum number of months with 80% of cases in the season. We also assessed whether co-circulation of A and B virus types affected the duration of influenza epidemics. Results: 212 influenza seasons and 571,907 cases were included from 30 countries. In tropical countries, the seasonal influenza activity lasted longer and the peaks of influenza A and B coincided less frequently than in temperate countries. Temporal characteristics of influenza epidemics were heterogeneous in the tropics, with distinct seasonal epidemics observed only in some countries. Seasons with co-circulation of influenza A and B were longer than influenza A seasons, especially in the tropics. Discussion: Our findings show that influenza seasonality is less well defined in the tropics than in temperate regions. This has important implications for vaccination programmes in these countries. High-quality influenza surveillance systems are needed in the tropics to enable decisions about when to vaccinate. The Global Influenza B Study is supported by an unrestricted research grant from Sanofi Pasteur. info:eu-repo/semantics/publishedVersion

Published
2016

9. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis

Author

Muthuri, Stella G., Venkatesan, Sudhir, Myles, Puja R., Leonardi Bee, Jo, Lim, Wei Shen, Al Mamun, Abdullah, Anovadiya, Ashish P., Araújo, Wildo N., Azziz Baumgartner, Eduardo, Báez, Clarisa, Bantar, Carlos, Barhoush, Mazen M., Bassetti, Matteo, Beovic, Bojana, Bingisser, Roland, Bonmarin, Isabelle, Borja Aburto, Victor H., Cao, Bin, Carratala, Jordi, Cuezzo, María R., Denholm, Justin T., Dominguez, Samuel R., Duarte, Pericles A. D., Dubnov Raz, Gal, Echavarria, Marcela, Fanella, Sergio, Fraser, James, Gao, Zhancheng, Gérardin, Patrick, Giannella, Maddalena, Gubbels, Sophie, Herberg, Jethro, Higuera Iglesias, Anjarath L., Hoeger, Peter H., Hoffmann, Matthias, Xiaoyun, Hu, Islam, Quazi T., Jiménez, Mirela F., Kandeel, Amr, Keijzers, Gerben, Khalili, Hossein, Khandaker, Gulam, Knight, Marian, Kusznierz, Gabriela, Kuzman, Ilija, Kwan, Arthur M. C., Lahlou Amine, Idriss, Langenegger, Eduard, Lankarani, Kamran B., Leo, Yee Sin, Linko, Rita, Liu, Pei, Madanat, Faris, Manabe, Toshie, Mayo Montero, Elga, Mcgeer, Allison, Memish, Ziad A., Metan, Gokhan, Mikić, Dragan, Mohn, Kristin G. I., Moradi, Ahmadreza, Nymadawa, Pagbajabyn, Ozbay, Bulent, Ozkan, Mehpare, Parekh, Dhruv, Paul, Mical, Poeppl, Wolfgang, Polack, Fernando P., Rath, Barbara A., Rodríguez, Alejandro H., Siqueira, Marilda M., Skrȩt Magierło, Joanna, Talarek, Ewa, Tang, Julian W., Torres, Antoni, Törün, Selda H., Tran, Dat, Uyeki, Timothy M., van Zwol, Annelies, Vaudry, Wendy, Velyvyte, Daiva, Vidmar, Tjasa, Zarogoulidis, Paul, Nguyen Van Tam, Jonathan S, de Lourdes Aguiar Oliveira, Maria, Al Khuwaitir, Tarig S. A., Al Masri, Malakita, Amin, Robed, Ballester Orcal, Elena, Bao, Jing, Basher, Ariful, Bautista, Edgar, Bertisch, Barbara, Bettinger, Julie, Booy, Robert, Bouza, Emilio, Bozkurt, Ilkay, Burgmann, Heinz, Čeljuska Tošev, Elvira, Chan, Kenny K. C., Chen, Yusheng, Chinbayar, Tserendorj, Cilloniz, Catia, Cox, Rebecca J., Sarrouf, Elena B., Cui, Wei, Dashti Khavidaki, Simin, Bin, Du, El Rhaffouli, Hicham, Escobar, Hernan, Florek Michalska, Agnieszka, Gerrard, John, Gormley, Stuart, Götberg, Sandra, Honarvar, Behnam, Jianming, Hu, Kemen, Christoph, Koay, Evelyn S. C., Kojic, Miroslav, Kudo, Koichiro, Kyaw, Win M., Leibovici, Leonard, Xiao li, Li, Hongru, Li, Libster, Romina, Loh, Tze P., Macbeth, Deborough, Maltezos, Efstratios, Marcone, Debora N., Marczynska, Magdalena, Mastalir, Fabiane P., Mickiene, Aukse, Moghadami, Mohsen, Moriconi, Lilian, Oliva, Maria E., Pečavar, Blaž, Poliquin, Philippe G., Rahman, Mahmudur, Rascon Pacheco, Alberto, Refaey, Samir, Schweiger, Brunhilde, Seale, Anna C., Sertogullarindan, Bunyamin, Smith, Fang G., Somer, Ayper, Souza, Thiago M. L., Stephan, Frank, Tabarsi, Payam, Tripathi, C. B., Viasus, Diego, Qin, Yu, Zhang, Wei, Zuo, Wei, Universitat de Barcelona, Ospedale 'Santa Maria della Misericordia' = University Hospital 'Santa Maria della Misericordia', Institut de Veille Sanitaire (INVS), Beijing Chao-Yang Hospital, Beijing Institute of Respiratory Diseases, Department of physics, engineering physics and astronomy, Queen's University [Kingston, Canada], Peking University People's Hospital, Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Centre National de la Recherche Scientifique (CNRS)-IRD-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de La Réunion (UR), National Perinatal Epidemiology Unit, University of Oxford [Oxford], Instituto Nacional de Enfermedades Respiratorias Dr. Emilio Coni [Santa Fe, Argentina] (INER), State Key Laboratory of Advanced Electromagnetic Engineering and Technology, Huazhong University of Science and Technology [Wuhan] (HUST), People's Hospital of Peking University (PKUPH), Université de La Réunion (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IRD-Centre National de la Recherche Scientifique (CNRS), University of Oxford, Muthuri, Stella G., Venkatesan, Sudhir, Myles, Puja R., Leonardi Bee, Jo, Lim, Wei Shen, Al Mamun, Abdullah, Anovadiya, Ashish P., Araújo, Wildo N., Azziz Baumgartner, Eduardo, Báez, Clarisa, Bantar, Carlo, Barhoush, Mazen M., Bassetti, Matteo, Beovic, Bojana, Bingisser, Roland, Bonmarin, Isabelle, Borja Aburto, Victor H., Cao, Bin, Carratala, Jordi, Cuezzo, María R., Denholm, Justin T., Dominguez, Samuel R., Duarte, Pericles A. D., Dubnov Raz, Gal, Echavarria, Marcela, Fanella, Sergio, Fraser, Jame, Gao, Zhancheng, Gérardin, Patrick, Giannella, Maddalena, Gubbels, Sophie, Herberg, Jethro, Higuera Iglesias, Anjarath L., Hoeger, Peter H., Hoffmann, Matthia, Xiaoyun, Hu, Islam, Quazi T., Jiménez, Mirela F., Kandeel, Amr, Keijzers, Gerben, Khalili, Hossein, Khandaker, Gulam, Knight, Marian, Kusznierz, Gabriela, Kuzman, Ilija, Kwan, Arthur M. C., Lahlou Amine, Idri, Langenegger, Eduard, Lankarani, Kamran B., Leo, Yee Sin, Linko, Rita, Liu, Pei, Madanat, Fari, Manabe, Toshie, Mayo Montero, Elga, Mcgeer, Allison, Memish, Ziad A., Metan, Gokhan, Mikić, Dragan, Mohn, Kristin G. I., Moradi, Ahmadreza, Nymadawa, Pagbajabyn, Ozbay, Bulent, Ozkan, Mehpare, Parekh, Dhruv, Paul, Mical, Poeppl, Wolfgang, Polack, Fernando P., Rath, Barbara A., Rodríguez, Alejandro H., Siqueira, Marilda M., Skrȩt Magierło, Joanna, Talarek, Ewa, Tang, Julian W., Torres, Antoni, Törün, Selda H., Tran, Dat, Uyeki, Timothy M., van Zwol, Annelie, Vaudry, Wendy, Velyvyte, Daiva, Vidmar, Tjasa, Zarogoulidis, Paul, Nguyen Van Tam, Jonathan S, de Lourdes Aguiar Oliveira, Maria, Al Khuwaitir, Tarig S. A., Al Masri, Malakita, Amin, Robed, Ballester Orcal, Elena, Bao, Jing, Basher, Ariful, Bautista, Edgar, Bertisch, Barbara, Bettinger, Julie, Booy, Robert, Bouza, Emilio, Bozkurt, Ilkay, Burgmann, Heinz, Čeljuska Tošev, Elvira, Chan, Kenny K. C., Chen, Yusheng, Chinbayar, Tserendorj, Cilloniz, Catia, Cox, Rebecca J., Sarrouf, Elena B., Cui, Wei, Dashti Khavidaki, Simin, Bin, Du, El Rhaffouli, Hicham, Escobar, Hernan, Florek Michalska, Agnieszka, Gerrard, John, Gormley, Stuart, Götberg, Sandra, Honarvar, Behnam, Jianming, Hu, Kemen, Christoph, Koay, Evelyn S. C., Kojic, Miroslav, Kudo, Koichiro, Kyaw, Win M., Leibovici, Leonard, Xiao li, Li, Hongru, Li, Libster, Romina, Loh, Tze P., Macbeth, Deborough, Maltezos, Efstratio, Marcone, Debora N., Marczynska, Magdalena, Mastalir, Fabiane P., Mickiene, Aukse, Moghadami, Mohsen, Moriconi, Lilian, Oliva, Maria E., Pečavar, Blaž, Poliquin, Philippe G., Rahman, Mahmudur, Rascon Pacheco, Alberto, Refaey, Samir, Schweiger, Brunhilde, Seale, Anna C., Sertogullarindan, Bunyamin, Smith, Fang G., Somer, Ayper, Souza, Thiago M. L., Stephan, Frank, Tabarsi, Payam, Tripathi, C. B., Viasus, Diego, Qin, Yu, Zhang, Wei, Zuo, Wei, Pediatric surgery, and ICaR - Circulation and metabolism

Subjects
Hospitalisation, Individual participant data meta-analyses, Influenza-related pneumonia, Neuraminidase inhibitors, Adolescent, Adrenal Cortex Hormones, Adult, Anti-Bacterial Agents, Antiviral Agents, Child, Child, Preschool, Enzyme Inhibitors, Female, Humans, Influenza, Human, Male, Middle Aged, Neuraminidase, Odds Ratio, Pneumonia, Viral, Treatment Outcome, Young Adult, Influenza A Virus, H1N1 Subtype, 0301 basic medicine, Epidemiology, [SDV]Life Sciences [q-bio], viruses, Meta-análises de dados de participantes individuais, Antibiotics, Pneumònia, Adrenal Cortex Hormone, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit, influenza-related pneumonia, neuraminidase inhibitors, 0302 clinical medicine, individual participant data meta‐analyses, Influenza A Virus, Enzyme Inhibitor, 030212 general & internal medicine, Viral, Incidence (epidemiology), Inibidores da neuraminidase, virus diseases, 3. Good health, Hospitalization, Infectious Diseases, Meta-analysis, Original Article, Individual participant data meta-analyse, Public Health, Human, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Antagonists & inhibitors, medicine.drug_class, influenza-related pneumonia, 030106 microbiology, influenza‐related pneumonia, Neuraminidase inhibitor, Ingressos i altes en els hospitals, Public Health, Environmental and Occupational Health, 03 medical and health sciences, Open Access, Pneumonia relacionada à gripe, Pharmacotherapy, Internal medicine, Anti-Bacterial Agent, medicine, H1N1 Subtype, Preschool, Antiviral Agent, Hospitalização, Hospital admission and discharge, business.industry, Environmental and Occupational Health, individual participant data meta-analyses, Original Articles, Odds ratio, Pneumonia, medicine.disease, Influenza, respiratory tract diseases, El Niño, Immunology, business
Abstract

Stella G. Muthuri,1 Sudhir Venkatesan,1 Puja R. Myles,1 Jo Leonardi-Bee,1 Wei Shen Lim,2 Abdullah Al Mamun,3 Ashish P. Anovadiya,4 Wildo N. Ara ujo,5 Eduardo Azziz-Baumgartner,6 Clarisa B aez,7 Carlos Bantar,8 Mazen M. Barhoush,9 Matteo Bassetti,10 Bojana Beovic,11 Roland Bingisser,12 Isabelle Bonmarin,13 Victor H. Borja-Aburto,14 Bin Cao,15 Jordi Carratala,16 Mar ıa R. Cuezzo,17 Justin T. Denholm,18 Samuel R. Dominguez,19 Pericles A. D. Duarte,20 Gal Dubnov-Raz,21 Marcela Echavarria,22 Sergio Fanella,23 James Fraser,24 Zhancheng Gao,25 Patrick G erardin,26,27,28,29 Maddalena Giannella,30 Sophie Gubbels,31 Jethro Herberg,32 Anjarath L. Higuera Iglesias,33 Peter H. Hoeger,34 Matthias Hoffmann,35 Xiaoyun Hu,36 Quazi T. Islam,37 Mirela F. Jim enez,38 Amr Kandeel,39 Gerben Keijzers,40 Hossein Khalili,41 Gulam Khandaker,42 Marian Knight,43 Gabriela Kusznierz,44 Ilija Kuzman,45 Arthur M. C. Kwan,46 Idriss Lahlou Amine,47 Eduard Langenegger,48 Kamran B. Lankarani,49 Yee-Sin Leo,50 Rita Linko,51 Pei Liu,52 Faris Madanat,53 Toshie Manabe,54 Elga Mayo-Montero,55 Allison McGeer,56 Ziad A. Memish,57,58 Gokhan Metan,59 Dragan Miki c,60 Kristin G. I. Mohn,61,62 Ahmadreza Moradi,63,64 Pagbajabyn Nymadawa,65 Bulent Ozbay,66 Mehpare Ozkan,67 Dhruv Parekh,68 Mical Paul,69 Wolfgang Poeppl,70 Fernando P. Polack,71,72 Barbara A. Rath,73 Alejandro H. Rodr ıguez,74 Marilda M. Siqueira,75 Joanna Skre zt-Magierło,76 Ewa Talarek,77 Julian W. Tang,78,79,80 Antoni Torres,81 Selda H. T€ or€un,82 Dat Tran,83 Timothy M. Uyeki,84 Annelies van Zwol,85 Wendy Vaudry,86 Daiva Velyvyte,87 Tjasa Vidmar,88 Paul Zarogoulidis,89 PRIDE Consortium Investigators* Jonathan S. Nguyen-Van-Tam1 1Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK. 2Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK. 3International Centre for Diarrhoeal Diseases, Research Bangladesh (ICDDRB), Dhaka, Bangladesh. 4Department of Pharmacology, Government Medical College and Sir Takhtsinhji General Hospital, Bhavnagar, Gujarat, India. 5University of Bras ılia, Bras ılia, DF, Brazil. 6Centers for Disease Control and Prevention, Atlanta, GA, USA. 7Ministerio de Salud de la Provincia de Buenos Aires, Buenos Aires, Argentina. 8Department of Infection Control, Hospital San Mart ın de Paran a, Entre R ıos, Argentina. 9Department of Medicine, King Saud Medical City, Riyadh, Saudi Arabia. 10Santa Maria Misericordia Hospital, Udine, Italy. 11Department of Infectious Diseases, University Medical Centre, Ljubljana, Slovenia. 12Department of Emergency Medicine, University Hospital Basel, Basel, Switzerland. 13Institut de Veille Sanitaire, Saint-Maurice, France. 14Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico. 15Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. 16Department of Infectious Diseases, Hospital Universitari de Bellvitge, Bellvitge Institute for Biomedical Research, L’Hospitalet de Llobregat, Red Espa~nola de Investigaci on en Patolog ıa Infecciosa, University of Barcelona, Barcelona, Spain. 17Ministerio de Salud de Tucum an, Tucum an, Argentina. 18Victorian Infectious Diseases Service and Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, Parkville, Vic., Australia. 19Department of Pediatric Infectious Diseases, Children’s Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA. 20Universidade Estadual do Oeste do Parana ´, UNIOESTE, Cascavel, PR, Brazil. 21The Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, Tel-Hashomer, Israel. 22Clinical Virology Laboratory, CEMIC University Hospital, Buenos Aires, Argentina. 23Section of Pediatric Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada. 24Paediatric Intensive Care Unit, Bristol Children’s Hospital, Bristol, UK. 25Department of Respiratory & Critical Care Medicine, Peking University People’s Hospital, Beijing, China. 26NICU/PICU, PFME, CHU Saint Pierre, Saint Pierre, La R eunion, France. 27CIC 1410 (CHU/Inserm/University of La Re ´union/URML-OI), CHU Saint Pierre, Saint Pierre, La Réunion, France. 28UMR PIMIT (CHU/Inserm/University of La Re ´union/IRD/CNRS), CYROI, Saint Denis – Reunion Island, Saint Denis, France. 29NICU/PICU CHU of La Re ´union, Groupe Hospitalier Sud Re ´union, Saint Pierre, La Re ´union, France. 30Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Maran ˜o ´n, Madrid, Spain. 31Department of Infectious Disease Epidemiology, Sector for National Health Documentation and Research, Statens Serum Institut, Copenhagen, Denmark. 32Section of Paediatrics, Division of Infectious Disease, Imperial College, London, UK. 33Epidemiology Research Unit, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosı ´o Villegas, Mexico City, Mexico. 34Cath. Children’s Hospital Wilhelmstift, Hamburg, Germany. 35Division of Infectious Diseases and Hospital Epidemiology, Kantonsspital St. Gallen, St. Gallen, Switzerland. 36Peking Union Medical College Hospital, Beijing, China. 37Dhaka Medical College Hospital, Dhaka, Bangladesh. 38Departamento de Ginecologia e Obstetrı ´cia – UFCSPA, Preceptora da Reside ˆncia Me ´dica do Hospital Fe ˆmina, Porto Alegre, Brazil. 39Ministry of Health in Egypt, Cairo, Egypt. 40Gold Coast Hospital, Gold Coast, Qld, Australia. 41Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. 42National Centre for Immunisation Research and Surveillance (NCIRS), The Children’s Hospital at Westmead, University of Sydney, Sydney, NSW, Australia. 43National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK. 44National Institute of Respiratory Diseases ‘Emilio Coni’ ANLIS “C. Malbran”, Santa Fe, Argentina. 45School of Medicine, University Hospital for Infectious Diseases, University of Zagreb, Zagreb, Croatia. 46Department of Intensive Care, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong. 47Faculty of Medicine and Pharmacy, Mohammed V Military Teaching Hospital, Biosafety Level 3 and Research Laboratory, University Mohammed V-Souissi, Rabat, Morocco. 48Department of Obstetrics and Gynaecology, Stellenbosch University and Tygerberg, Stellenbosch, South Africa. 49Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. 50Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore. 51Helsinki University Hospital, Helsinki, Finland. 52Department of Infectious Diseases, The First Affiliated Hospital, China Medical University, Shenyang, China. 53Department of Pediatrics, King Hussein Cancer Center, Amman, Jordan. 54Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan. 55Instituto de Medicina Preventiva de la Defensa, Capitan Medico Ramon y Cajal (IMPDEF), Ministerio de Defensa, Madrid, Spain. 56Toronto Invasive Bacterial Diseases Network, University of Toronto, Toronto, ON, Canada. 57Ministry of Health, Riyadh, Saudi Arabia. 58College of Medicine, Alfaisal University, Riyadh, Saudi Arabia. 59Department of Infectious Diseases and Clinical Microbiology, Erciyes University Faculty of Medicine, Kayseri, Turkey. 60Military Medical Academy, Clinic for Infectious and Tropical Diseases, Belgrade, Serbia. 61Section for Infectious Diseases, Medical Department, and Department of Research and Development, Haukeland University Hospital, Bergen, Norway. 62Department of Clinical Science, The Influenza Centre, University of Bergen, Bergen, Norway. 63The Division of Ocular Immunology, Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 64National Research Institute for Tuberculosis and Lung Disease, Massih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 65National Influenza Center, National Center of Communicable Diseases, Ministry of Health, Ulaanbaatar, Mongolia. 66Department of Pulmonary and Critical Care, Yuzuncu Yil University Medical Faculty, Van, Turkey. 67Clinic of Pediatric Neurology, Dr. Sami Ulus Research and Training Hospital of Women’s and Children’s Health and Diseases, Ankara, Turkey. 68Critical Care and Pain Perioperative, Critical Care and Trauma Trials Group, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK. 69Division of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel. 70Medical University of Vienna, Vienna, Austria. 71Department of Pediatrics, Vanderbilt Vaccine Center, Vanderbilt University, Nashville, TN, USA. 72Fundacion INFANT, Buenos Aires, Argentina. 73Division of Pneumonology-Immunology, Department of Pediatrics, Charite ´ University Medical Center, Berlin, Germany. 74Critical Care Department, Hospital Joan XXIII, IISPV, URV, CIBERES, Tarragona, Spain. 75Laboratory of Respiratory Viruses, Oswaldo Cruz Institute/Fiocruz, Rio de Janeiro, Brazil. 76Uniwersytet Rzeszowski, Rzeszo ´w, Poland. 77Department of Children’s Infectious Diseases, Medical University of Warsaw, Warsaw, Poland. 78Division of Microbiology/Molecular Diagnostic Centre, Department of Laboratory Medicine, National University Hospital, Singapore, Singapore. 79Alberta Provincial Laboratory for Public Health, University of Alberta Hospital, Edmonton, Canada. 80Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada. 81Hospital Clinic, University of Barcelona, IDIBAPS, CIBERES, Barcelona, Spain. 82Department of Pediatric Infectious Diseases, Istanbul Medical Faculty, Istanbul, Turkey. 83Division of Infectious Diseases, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Canada. 84Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. 85Department of Pediatric Intensive Care, VU University Medical Center, Amsterdam, The Netherlands. 86Division of Infectious Diseases, Department of Pediatrics, Stollery Children’s Hospital, University of Alberta, Edmonton, AB, Canada. 87Lithuanian University of Health Sciences, Kaunas, Lithuania. 88General Hospital, Slovenj Gradec, Slovenia. 89Unit of Infectious Diseases, University General Hospital of Alexandroupolis, Democritus University Thrace, Dragana, Greece. Correspondence: Jonathan S. Nguyen-Van-Tam, University of Nottingham, City Hospital, DM, Room A28b, Clinical Sciences Building, Nottingham NG5 1PB, UK. E-mail: jvt@nottingham.ac.uk *List of PRIDE Consortium Investigators are in Appendix 1. For affiliations, please see Table S1. Múltipla - ver em notas Background The impact of neuraminidase inhibitors (NAIs) on influenza-related pneumonia (IRP) is not established. Our objective was to investigate the association between NAI treatment and IRP incidence and outcomes in patients hospitalised with A(H1N1) pdm09 virus infection. Methods A worldwide meta-analysis of individual participant data from 20 634 hospitalised patients with laboratory-confirmed A (H1N1)pdm09 (n = 20 021) or clinically diagnosed (n = 613) ‘pandemic influenza’. The primary outcome was radiologically confirmed IRP. Odds ratios (OR) were estimated using generalised linear mixed modelling, adjusting for NAI treatment propensity, antibiotics and corticosteroids. Results Of 20 634 included participants, 5978 (29 0%) had IRP; conversely, 3349 (16 2%) had confirmed the absence of radiographic pneumonia (the comparator). Early NAI treatment (within 2 days of symptom onset) versus no NAI was not significantly associated with IRP [adj. OR 0 83 (95% CI 0 64–1 06; P = 0 136)]. Among the 5978 patients with IRP, early NAI treatment versus none did not impact on mortality [adj. OR = 0 72 (0 44–1 17; P = 0 180)] or likelihood of requiring ventilatory support [adj. OR = 1 17 (0 71– 1 92; P = 0 537)], but early treatment versus later significantly reduced mortality [adj. OR = 0 70 (0 55–0 88; P = 0 003)] and likelihood of requiring ventilatory support [adj. OR = 0 68 (0 54– 0 85; P = 0 001)]. Conclusions Early NAI treatment of patients hospitalised with A (H1N1)pdm09 virus infection versus no treatment did not reduce the likelihood of IRP. However, in patients who developed IRP, early NAI treatment versus later reduced the likelihood of mortality and needing ventilatory support.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results